Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants

dc.contributor.authorJaumdally, S.
dc.contributor.authorTomasicchio, M.
dc.contributor.authorPooran, A.
dc.contributor.authorEsmail, A.
dc.contributor.authorKotze, A.
dc.contributor.authorMeier, S.
dc.contributor.authorWilson, L.
dc.contributor.authorOelofse, S.
dc.contributor.authorVan der Merwe, C.
dc.contributor.authorRoomaney, A.
dc.contributor.authorDavids, M.
dc.contributor.authorSuliman, T.
dc.contributor.authorJoseph, R.
dc.contributor.authorPerumal, T.
dc.contributor.authorScott, A.
dc.contributor.authorShaw, M.
dc.contributor.authorPreiser, W.
dc.contributor.authorWilliamson, C.
dc.contributor.authorGoga, Ameena Ebrahim
dc.contributor.authorMayne, E.
dc.contributor.authorGray, G.
dc.contributor.authorMoore, P.
dc.contributor.authorSigal, A.
dc.contributor.authorLimberis, J.
dc.contributor.authorMetcalfe, J.
dc.contributor.authorDheda, K.
dc.date.accessioned2025-02-26T05:48:52Z
dc.date.available2025-02-26T05:48:52Z
dc.date.issued2024-03-05
dc.descriptionDATA AVAILABILITY : All data generated and analyzed in this study are included in the paper and its Supplementary section. Individual participant datawill bemade available to researchers who provide a protocol that is approved by their respective human research ethics committee. All protocols will be reviewed and approved by the CAS COVID consortiumtrial steering committee up to five years following publication. A data sharing agreement (DTA) will need to be concluded between the representatives of the requesting institution and the University of Cape Town Lung Institute. Data sharing requests should be directed to keertan. dheda@uct.ac.za. Table S6 provides the accession codes for the WGS of the SARS-CoV-2 variants that could be sequenced for this study. The rawreads and rawcount file for the RNAseq experiment has been deposited on the GEO website under the accession number GSE252508.en_US
dc.description.abstractAirborne transmission of SARS-CoV-2 aerosol remains contentious. Importantly, whether cough or breath-generated bioaerosols can harbor viable and replicating virus remains largely unclarified. We performed size-fractionated aerosol sampling (Andersen cascade impactor) and evaluated viral culturability in human cell lines (infectiousness), viral genetics, and host immunity in ambulatory participants with COVID-19. Sixty-one percent (27/44) and 50% (22/44) of participants emitted variant-specific culture-positive aerosols <10μmand <5μm, respectively, for up to 9 days after symptom onset. Aerosol culturability is significantly associated with lower neutralizing antibody titers, and suppression of transcriptomic pathways related to innate immunity and the humoral response. A nasopharyngeal Ct <17 rules-in ~40% of aerosol culture-positives and identifies those who are probably highly infectious. A parsimonious three transcript blood-based biosignature is highly predictive of infectious aerosol generation (PPV > 95%). There is considerable heterogeneity in potential infectiousness i.e., only 29% of participants were probably highly infectious (produced culture-positive aerosols <5μm at ~6 days after symptom onset). These data, which comprehensively confirm variant-specific culturable SARS-CoV-2 in aerosol, informthe targeting of transmission-related interventions and public health containment strategies emphasizing improved ventilation.en_US
dc.description.departmentPaediatrics and Child Healthen_US
dc.description.librarianam2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThe South African Medical Research Council; the Center for Emerging and Neglected Diseases; the European and Developing Countries Clinical Trials Partnership; UK Medical Research Council and the Wellcome Trust.en_US
dc.description.urihttps://www.nature.com/ncomms/en_US
dc.identifier.citationJaumdally, S., Tomasicchio, M., Pooran, A. et al. 2024, 'Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants', Nature Communications, vol. 15, art. 2003, pp. 1-13. https://DOI.org/10.1038/s41467-024-45400-1.en_US
dc.identifier.issn2041-1723 (online)
dc.identifier.other10.1038/s41467-024-45400-1
dc.identifier.urihttp://hdl.handle.net/2263/101215
dc.language.isoenen_US
dc.publisherNature Researchen_US
dc.rights© The Author(s) 2024. Open access. This article is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.subjectCoughen_US
dc.subjectTransmissionen_US
dc.subjectCOVID-19 pandemicen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.subjectAirborne transmissionen_US
dc.titleFrequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variantsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Jaumdally_Frequency_2024.pdf
Size:
2.18 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: